星期三盘前交易时段，丹纳赫公司（NYSE: DHR）股价下跌。公司报告第四季度调整后每股收益为$2.14，未达到预期的$2.16。季度销售额为$65.4亿（+2%），高于分析师预期的$64.2亿。 生物技术部门季度同比增长6.5%，而生命科学部门增长5.5%。诊断部门销售额同比下降3%。 公司以$20.78亿的现金及等价物和$23.30亿的库存结束了本季度。 丹纳赫的长期债务截止季度末总计$155亿。第四季度经营现金流为$20亿，非GAAP自由现金流为$15亿。 总裁兼首席执行官Rainer M. Blair表示：“我们团队的良好执行也推动了强劲的现金流和营业利润率扩展。” 展望未来，丹纳赫预计第一季度非GAAP核心收入将同比下降低个位数百分比。 然而，公司预计2025年全年核心收入将同比增长3%。 Blair继续说道：“展望未来，我们认为丹纳赫比我们40年历史中的任何时候都处于更好的位置。” “我们近几年在投资组合中的转型使我们成为专注的生命科学和诊断创新者，准备实现更高的长期增长，扩展利润率和更强的现金流。” 上市后价格变动：截至周三最后检查，DHR股价盘前下跌5.48%，至$234.26。

以上内容来自Benzinga Earnings专栏，原文如下：

Danaher Corporation (NYSE:DHR) shares are trading lower in the premarket session on Wednesday.

The company reported fourth-quarter adjusted earnings per share of $2.14 missing the street view of $2.16. Quarterly sales of $6.54 billion (+2%) beat the analyst consensus estimate of $6.42 billion.

The Biotechnology segment gained 6.5% year over year in the quarter under review, while the Life Sciences segment rose 5.5%. The Diagnostics segment sales decreased by 3% year over year.

The company exited the quarter with cash and equivalents worth $2.078 billion, and inventories worth $2.330 billion.

Also Read: Nasdaq Jumps 2% After Nvidia, Other Tech Stocks Bounce Back From DeepSeek Hit: Greed Index Remains In ‘Fear’ Zone

Danaher’s long-term debt as of quarter end totaled $15.50 billion. Operating cash flow was $2.0 billion in the fourth quarter and non-GAAP free cash flow was $1.5 billion.

Rainer M. Blair, President and Chief Executive Officer, stated, “Good execution by our team also drove solid cash flow and operating margin expansion.”

Outlook: Danaher expects its non-GAAP core revenue to decline by a low-single digit percentage year-over-year in the first quarter.

However, it anticipates a 3% year-over-year increase in core revenue for the full year of 2025.

Blair continued, “Looking ahead, we believe Danaher is better positioned than at any point in our 40-year history”. 

“The transformation in our portfolio over the last several years has created a focused life sciences and diagnostics innovator, poised for higher long-term growth, expanded margins and stronger cash flow.”

Price Action: DHR shares are trading lower by 5.48% to $234.26 premarket at last check Wednesday.

Read Next:

• Jim Cramer Recommends Buying ‘Fabulous' BlackRock, Calls Coterra Energy The ‘Cheapest' Natural Gas Company

Photo via Shutterstock.